Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials.
White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, Cobelens F, Ernst JD, Esmail H, Garcia-Basteiro AL, Hadinegoro SR, Hanekom WA, Hatherill M, Hill PC, Muloiwa R, Pelzer PT, Rangaka L, Rees H, Schrager L, Stanley M, Tufet M, Wong EB, Houben RMGJ.
White RG, et al. Among authors: horton kc.
Lancet Respir Med. 2025 Oct;13(10):933-942. doi: 10.1016/S2213-2600(25)00164-X. Epub 2025 Jul 3.
Lancet Respir Med. 2025.
PMID: 40618773
Review.